What the study measured
Twenty-one night-shift workers received a low-dose melatonin regimen or placebo for seven days. Endogenous melatonin profiles were measured on the eighth day, and secretion amplitude was unchanged by treatment. [1]
The report also described one blind participant after 37 days of a much higher dose, again without a changed endogenous profile. That single observation cannot establish the safety or physiological effect of high-dose use in a wider population. [1]
How far the finding goes
These findings do not support the blanket claim that brief supplementation inevitably stops natural production. They also do not demonstrate that every secretion characteristic, formulation, population or long-term exposure is unaffected. Funding and conflicts were not established from the abstract. [1]
Secretion amplitude and the timing of a rhythm are separate features. Preserving amplitude does not by itself establish unchanged timing, absence of symptoms or comprehensive long-term safety. A question about production therefore should not be treated as identical to a question about all effects of continued use. [1]
A hypothetical distinction
Imagine a daily curve shifts to a different clock time while keeping the same height. Its amplitude has stayed constant, but its timing has changed.
| Detail | Interpretation |
|---|---|
| 21 shift workers | Short group experiment |
| One additional person | Separate case observation |
| Amplitude | Not comprehensive safety |

Sources for this article
- The amplitude of endogenous melatonin production is not affected by melatonin treatment in humans - PubMed
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.